• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lyell Immunopharma, Inc. - Common Stock (NQ:LYEL)

15.76 +0.76 (+5.07%)
Delayed Quote Updated: 9:30 AM EST, Nov 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 8,934
Open 15.75
Bid (Size) 15.01 (100)
Ask (Size) 15.61 (100)
Prev. Close 15.00
Today's Range 15.75 - 15.84
52wk Range 7.195 - 45.00
Shares Outstanding 240,471,497
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Lyell Immunopharma Targets Mid-2027 Pivotal Data for Lymphoma CAR-T Therapy ↗
Today 3:14 EST
Lyell Immunopharma (NASDAQ:LYEL) expects pivotal data in mid-2027 for its lead CAR-T cell therapy, ronde-cel, as the company advances the treatment in patients with large B-cell lymphoma who have... 
Via MarketBeat
News headline image
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2026
November 04, 2026
From Lyell Immunopharma, Inc
Via GlobeNewswire

Performance

52-Week Range 65.0% below 52-week high
15.76
7.2052W Low 45.0052W High
1 Week 5.8% below 1-week high
10.561W Low 16.731W High

Lyell Immunopharma, Inc. - Common Stock (LYEL) traded between $7.20 and $45.00 over the past 52 weeks and last traded at $15.76, 65.0% below its 52-week high. Over the past week it ranged between $10.56 and $16.73.

Past 12 Months
+42.8%
+83.0%
+10.9%
-21.4%
-45.6%
-4.7%
1W +$4.72
1M +$7.15
3M +$1.55
6M -$4.30
YTD -$13.22
1Y -$0.78

LYEL was -4.7% over the past year, -21.4% over six months, -45.6% year to date, +42.8% in the last week.

12 Months vs Market
LYEL
-4.7%
DIA
+7.8%
SPY
+8.6%
QQQ
+5.5%
IWM
+10.9%

Over the past 12 months LYEL returned -4.7% versus DIA (Dow) +7.8%, SPY (S&P 500) +8.6%, QQQ (Nasdaq 100) +5.5% and IWM (Russell 2000) +10.9%.

Volume & Liquidity 0.05× 3-mo avg
Today 8,934 3-mo avg 167.0K
1W
410.9K
1M
220.8K
3M
167.0K
6M
169.4K
YTD
139.9K
1Y
130.7K

LYEL most recently traded 8,934 shares against a 3-month average daily volume of 167.0K.

More News

Read More
Today's US Session Top Gainers and Losers: TNONW and CENN Lead ↗
November 04, 2026
Via Chartmill
Top U.S. Stock Movers: Nov. 4, 2026 Gainers and Losers ↗
November 04, 2026
Via Chartmill
US Gap Movers for Nov. 4, 2026: Sharp Opens in Both Directions ↗
November 04, 2026
Via Chartmill
News headline image
Lyell Immunopharma Announces $80 Million Private Placement to Advance Ronde-Cel Toward Planned BLA Submission
November 04, 2026
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Lyell Immunopharma to Present Positive Updated Ronde-Cel Data in More than 80 Patients at ASH 2026 from PiNACLE Pivotal Trial in 3L+ and from Phase 1/2 2L Cohort in Patients with Relapsed/Refractory Large B-Cell Lymphoma
November 04, 2026
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Lyell Immunopharma To Participate in November Investor Events
November 02, 2026
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Lyell Immunopharma To Participate in the Baird 2026 Global Healthcare Conference
September 14, 2026
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Lyell Immunopharma Completes Manufacturing Transfer for LYL273 and Provides Updated Timeline on Phase 1/2 Trial in Metastatic Colorectal Cancer
September 10, 2026
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026
August 06, 2026
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Lyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
June 25, 2026
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European Hematology Association 2026 Congress
June 12, 2026
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Lyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansion
June 08, 2026
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Lyell Immunopharma to Present Phase 1/2 Safety and Translational Data for Ronde-Cel in Large B-Cell Lymphoma at the European Hematology Association 2026 Congress
June 04, 2026
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Lyell Immunopharma Announces Participation in Goldman Sachs 47th Annual Global Healthcare Conference 2026
June 01, 2026
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Lyell Immunopharma Targets 2027 FDA Filing as CAR-T Pipeline Advances ↗
May 27, 2026
Via MarketBeat
News headline image
Lyell Immunopharma Announces Participation in May Investor Conferences
May 12, 2026
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026
May 06, 2026
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Lyell Immunopharma Announces Participation in 25th Annual Needham Virtual Healthcare Conference
April 07, 2026
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results
March 12, 2026
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer
March 09, 2026
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Lyell Immunopharma Announces Participation in March Investor Conferences
February 23, 2026
From Lyell Immunopharma, Inc
Via GlobeNewswire
The market is filled with gapping stocks in Wednesday's session. ↗
February 18, 2026
Via Chartmill
News headline image
Lyell Immunopharma Announces Initiation of Patient Dosing in First-of-Its-Kind Phase 3 Head-To-Head CAR T-Cell Clinical Trial in Aggressive Large B-Cell Lymphoma
February 12, 2026
From Lyell Immunopharma, Inc
Via GlobeNewswire

Frequently Asked Questions

Is Lyell Immunopharma, Inc. - Common Stock publicly traded?
Yes, Lyell Immunopharma, Inc. - Common Stock is publicly traded.
What exchange does Lyell Immunopharma, Inc. - Common Stock trade on?
Lyell Immunopharma, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Lyell Immunopharma, Inc. - Common Stock?
The ticker symbol for Lyell Immunopharma, Inc. - Common Stock is LYEL on the Nasdaq Stock Market
What is the current price of Lyell Immunopharma, Inc. - Common Stock?
The current price of Lyell Immunopharma, Inc. - Common Stock is 15.76
When was Lyell Immunopharma, Inc. - Common Stock last traded?
The last trade of Lyell Immunopharma, Inc. - Common Stock was at 11/06/26 09:30 AM ET
What is the market capitalization of Lyell Immunopharma, Inc. - Common Stock?
The market capitalization of Lyell Immunopharma, Inc. - Common Stock is 3.79B
How many shares of Lyell Immunopharma, Inc. - Common Stock are outstanding?
Lyell Immunopharma, Inc. - Common Stock has 4B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap